We give ourselves to our work, but it also gives to us. We find joy when we take pride, recognize one another and have fun.

We believe that every person deserves to be seen, heard and cared for. This happens when we are inclusive, act with integrity and reduce health care disparities.

We can only change patients’ lives when we perform at our best together. This happens when we focus on what matters, agree who does what and measure our outcomes.

Breakthroughs start by challenging convention, especially in the face of uncertainty or adversity. This happens when we think big, speak up and are decisive.

Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942.

Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization.

Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 

1. Unleash the power of our people; 
2. Deliver first-in-class science; 
3. Transform our go-to-market model; 
4. Win the digital race in pharma; and 
5. Lead the conversation.


Biotechnology

Health & Wellness

Health Care

Manufacturing

Pharmaceutical

Therapeutics

Pfizer

Vandana Mediboyina

Sarah Grimwood

Mr. Malik joined Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm’s U.S. operations. Previously, he led the firm’s Global Pharmaceuticals & Medical Products practice.

At Pfizer, Mr. Malik oversees the company’s strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payers and governments around the world.

Mr. Malik earned a Bachelor of Science in finance from Indiana University and currently serves on the University’s Kelley School of Business Dean’s Council. He is an active advocate for bettering the lives of people with food allergies and has lived and worked globally including in the U.S., Europe, Asia, Latin America, and Africa.

Aamir Malik

Aida Habtezion is Senior Vice President, Chief Medical Officer at [Pfizer](/org/pfizer). Habtezion took a leave of absence from Stanford in November of 2020 to pursue the role. In addition to the CMO job, she also heads [Pfizer](/org/pfizer)'s worldwide medical and safety unit within worldwide research, development and medicine.

As a Professor at Stanford, her focus was gastroenterology and hepatology, but she also was a member of the immunology Ph.D. faculty and the Institute for Immunity, Transplantation and Infection.

A native of Eritrea, Habtezion joined Stanford as an assistant professor in December 2010. She most recently led a [National Institutes of Health](/org/national-institutes-of-health) translational lab trying to identify potential immune-based therapeutic targets for pancreatitis and inflammatory bowel disease.

Aida Habtezion

Mike McDermott is currently the EVP, Chief Global Supply Officer at [Pfizer](/org/pfizer). Mike has held this position since January 2014. Prior to this, they were the Vice President, Global Supply Chain at [Pfizer](/org/pfizer) from January 2003 to December 2013.

Mike McDermott has a Master of Science in Industrial Engineering from the [New Jersey Institute of Technology](/org/new-jersey-institute-of-technology) and a Bachelor's of Science in Industrial Engineering from the same school.

They work with David M. Denton - EVP, CFO, Payal Sahni - EVP, CHRO, and Aamir Malik - EVP, Chief Business Innovation Officer. Mike McDermott reports to Albert Bourla, Chairman & CEO.

Mike McDermott

Clarence R. Manuel is a senior scientist at Pfizer's Viral Vaccines department. Clarence has dedicated their career to researching and developing treatments for heart disease and diabetes. Clarence has worked at the American Heart Association, Einstein-Mount Sinai Diabetes Center, and NYIT's Weill Cornell Medicine, among other institutions. In 2018, they were awarded the American Society for Cell Biology/EMBO Annual Meeting's prestigious "Outstanding Abstract" award.

Clarence R. Manuel has a Doctor of Philosophy (PhD) in Pharmacology from St. John's University, a Masters of Biomedical Science in Pharmacological Sciences from Rutgers New Jersey Medical School, and a Bachelor of Arts (B.A.) in English Language and Literature, General from College of Saint Benedict and Saint John's University. Clarence also has a High School Diploma from St. Benedict's Prep School and a certification from The New York Academy of Sciences in 2016 Science Alliance Leadership Training (SALT).



Clarence R. Manuel

David M. Denton joined as CFO in May 2022 from Lowe’s Companies, Inc. where he most recently served in the same role. Mr. Denton has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. 

Prior to joining [Lowe's](/org/lowes) in 2018, Mr. Denton served as Executive Vice President and CFO of [CVS Health](/org/cvs-health), where he was responsible for all aspects of their financial planning and management. He played a key role in CVS’s transformational journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, Mr. Denton played a pivotal role in CVS’s acquisition of Aetna, structuring and negotiating the terms and financing for the transaction.

Before becoming CFO at CVS, Mr. Denton held several leadership roles, including senior vice president and controller/chief accounting officer. Prior to CVS, he was with the management consulting firm of Deloitte Touche Tohmatsu.

He earned a bachelor's degree in business administration from [Kansas State University](/org/kansas-state-university), USA and an MBA from the Babcock Graduate School of Management at Wake Forest University, USA. He serves on the board of Tapestry, Inc.

David M. Denton

Husain Miyajiwala

Steve First is the VP of Global Benefits at [Pfizer](/org/pfizer). Steve has over 20 years of experience in the benefits field. Steve started their career as a consultant at Hewitt Associates in 1996. Steve then moved to Watson Wyatt Worldwide in 2001, where they were a senior consultant until 2005. In their current role at [Pfizer](/org/pfizer), they are responsible for designing and administering employee benefits programs for [Pfizer](/org/pfizer)’s 80,000 employees around the world.

Steve First attended the [University of Pennsylvania](/org/university-of-pennsylvania), where they earned a Bachelor of Science in mathematics.

Steve First reports to Payal Sahni, EVP, CHRO. Steve First works with and Dave Binder - VP, Talent & Organizational Effectiveness.

Steve First

Lev Kubiak is the current Vice President and Chief Security Officer at [Pfizer](/org/pfizer). Prior to this, they served as the Assistant Director of International Operations for Homeland Security Investigations at the Department of Homeland Security from November 1992 to September 2016. Lev has dedicated their career to protecting and investigating crimes against the United States.

Lev Kubiak has a Master's degree in Public Administration/International Management from George Mason University - Schar School of Policy and Government. Lev also has a Certificate in International Comparative Political and Economic Systems (ICPES) from [Georgetown University](/org/georgetown-university). Lev Kubiak's undergraduate degree is a Bachelor of Arts - BA in English Literature/Political Studies from [Mercyhurst University](/org/mercyhurst-university).

Lev Kubiak reports to Rady Johnson, EVP, Chief Compliance, Quality & Risk Officer. Some of their coworkers include Guy Delp - VP, Global Information Security, Sue Diviney - VP, Office of the Ombuds Lead, and Carol Bye - VP, Regulatory Quality Assurance.

Lev Kubiak

Seng H Cheng is the current SVP, Chief Scientific Officer - Rare Disease Unit at [Pfizer](/org/pfizer). Seng has previously worked as the Global Head of Research for Rare Diseases at Sanofi from January 2011 to July 2018. Prior to that, they were the Group Vice President, Genetic Diseases Science at Genzyme from January 1989 to December 2011. Cheng started their career as a Staff Scientist at Integrated Genetics from January 1985 to December 1989, and before that they were a Postdoctoral Fellow at the National Institute for Medical Research from January 1983 to December 1985.

Seng H Cheng received a Ph.D. in Biochemistry from the [University of London](/org/university-of-london) and a B.Sc. in Biochemistry from the [University of London](/org/university-of-london). Seng also studied Chemistry, Physics and Mathematics at [Culford School](/org/culford-school).

Katherine Beaverson - Senior Director, Patient Advocacy Lead - Rare Disease Unit, Ken Rhodes - VP, Rare Neurology & Discovery Biology, and Clark Pan - VP, Gene Therapy and Discovery Biology report to Seng H Cheng. They are on a team with William C. Sessa - SVP, Chief Scientific Officer - Internal Medicine Research Unit, Jeff Settleman - SVP, Chief Scientific Officer - Oncology Research & Development. Their manager is Mikael Dolsten, Chief Scientific Officer & President, WW Research, Development & Medical.

Seng H Cheng

Katherine Beaverson is currently the Senior Director, Patient Advocacy Lead - Rare Disease Unit at [Pfizer](/org/pfizer). Katherine has over 15 years of experience in the biotech and pharmaceutical industry, with a focus on rare and orphan diseases. 

Katherine started their career as a Genetic Counselor and Research Program Coordinator at Weill Cornell Medical College, where they worked for 8 years. In 2004, they were recruited by Memorial Sloan-Kettering Cancer Center to help establish their new Ophthalmic Oncology Service. After a successful launch, Katherine moved on to [Amicus Therapeutics](/org/amicus-therapeutics) in 2005, where they established their Patient Advocacy department and led global strategy across three disease platforms. 

In 2009, Katherine returned to [Pfizer](/org/pfizer) as a Consultant, providing strategic consultancy to the Established Products Business Unit for market launch and business growth opportunities in orphan disease products. In their current role as Senior Director, Patient Advocacy Lead - Rare Disease Unit, Katherine is responsible for leading [Pfizer](/org/pfizer)'s patient advocacy efforts for rare disease patients and families.

Katherine Beaverson has a Master of Science in Human/Medical Genetics from [Sarah Lawrence College](/org/sarah-lawrence-college) and a Bachelor of Arts from [Swarthmore College](/org/swarthmore-college).

They are on a team with Michael Binks - VP, Clinical Research, Greg Larosa - VP, Head of Scientific Research, and Ken Rhodes - VP, Rare Neurology & Discovery Biology. Their manager is Seng H Cheng, SVP, Chief Scientific Officer - Rare Disease Unit.

Katherine Beaverson

Clark Pan is the current Vice President of Gene Therapy and Discovery Biology at [Pfizer](/org/pfizer). Prior to this, they served as the Acting Head of Legacy Shire Research US from February 2019 to August 2019. Before that, they were the Vice President and Head of Discovery Therapeutics at Shire from July 2014 to January 2019. In this role, they were responsible for setting overall new molecular entity strategy that delivers preclinical development candidates consistent with the strategic objectives and mission of Shire. Clark was also responsible for introducing new enabling technologies and identifying external opportunities that help ensure the achievement of productivity goals. Additionally, they were responsible for developing and integrating operating and strategic plans that support the overall Shire Research goals, including optimizing the internal versus external resource balance of key functions. Major functions within Molecule Optimization that they oversaw include molecular design, molecule optimization, medicinal chemistry, oligonucleotide and peptide chemistry, molecular biology, protein chemistry, antibody engineering, phage library design and screening, gene therapy vector technology, computer aided drug design, project leadership and management of external partnerships. Clark has also effectively engaged external scientific organizations and managed complex network of strategic CRO partnerships. Clark is capable of representing the Company in all related technical matters of high significance and is a member of the Shire Research and Non-clinical Development Leadership Team.

Clark Pan received their PhD in Molecular Biology from the University of California, Los Angeles. Clark also holds a BS and BA in Genetics and Chemistry from [UC Davis](/org/uc-davis-transplant-center). Clark received their high school diploma from the International Studies Academy.

They are on a team with Sarah Grimwood - Executive Director & Head of Portfolio, Strategy & Operations - Rare Disease Unit, Katherine Beaverson - Senior Director, Patient Advocacy Lead - Rare Disease Unit, and Michael Binks - VP, Clinical Research. Their manager is Seng H Cheng, SVP, Chief Scientific Officer - Rare Disease Unit.

Clark Pan

Mike Sweitzer is currently the VP, Global Commercial Operations - Emerging Markets at [Pfizer](/org/pfizer). Prior to this, they were the General Manager of [Pfizer](/org/pfizer) Caribbean in Puerto Rico from January 1998 to December 2005. In this role, they were responsible for effectively managing the development and implementation of a business operating plan for a 26-island venture with a $250MM P&L. Mike also directed 9 executives and 360 colleagues, driving the success of new product introductions and marketing strategies.

Sweitzer has also represented the interests of [Pfizer](/org/pfizer) to key stakeholders and influencers in local government, academic institutions media, patient care associations, community outreach leaders and other organizations. Mike has also developed Sales & Marketing strategies for a full [Pfizer](/org/pfizer) portfolio of branded products.

Mike Sweitzer has a Bachelor of Science in Hotel Restaurant & Institutional Management from [Penn State University](/org/penn-state). Mike also has two Masters of Science, one in Information and Telecommunications Systems Management and the other in Systems Management, both from Capitol Technology University.

Their manager is Aamir Malik, EVP, Chief Business Innovation Officer. Mike Sweitzer works with Eileen Cheigh - VP, Business Assessment - Chief Business Office, Gautam Gupta - SVP, Head of Strategy & Consulting, and Aaron Foster - VP, Business Analytics & Insights.

Mike Sweitzer

Carol Bye is a pharmaceutical executive with over 25 years of experience in the industry. Carol currently serves as the Vice President of Regulatory Quality Assurance at [Pfizer](/org/pfizer). In this role, they are responsible for overseeing the quality of [Pfizer](/org/pfizer)'s research and development initiatives as well as its medical functions worldwide.

Prior to their current role, Carol served as the Vice President of Quality Assurance GMP at [Pfizer](/org/pfizer). In this role, they were responsible for quality oversight of both internal and contract manufacturing of biologics, vaccines, devices, and small molecule products. During their time in this role, they also had significant interaction with various regulatory agencies.

Before joining [Pfizer](/org/pfizer), Carol held various roles at [AstraZeneca](/org/astrazeneca), including Senior Process Engineer and Technical Leadersip roles in manufacturing and quality assurance.

Carol Bye holds a BEng in Chemical Engineering from University College Dublin.

Carol Bye reports to Rady Johnson, EVP, Chief Compliance, Quality & Risk Officer. Some of their coworkers include Sue Diviney - VP, Office of the Ombuds Lead, Guy Delp - VP, Global Information Security, and Lev Kubiak - VP, Chief Security Officer.

Carol Bye

Guy Delp is currently the VP of Global Information Security at [Pfizer](/org/pfizer). Guy has over 15 years of experience in the IT industry, with a focus on security. Guy started their career at [Lockheed Martin](/org/lockheed-martin) in 2001 as a Senior Program Manager. Guy held various positions within business development, ranging from capture management to developing international opportunity pipelines and driving new market growth in whitespace areas through emerging technologies and products. In 2014, they became the Engineering Director for Cyber & Data Analytics. In this role, they were responsible for leading the transformation strategy of the Network Assurance and Computer Network Defense mission across a global workforce for the Defense Information Systems Agency (DISA). Guy has been instrumental in the success of multiple global Security Operations Centers and 24x7x365 Network Defense.

Guy Delp has a Bachelor in Computer Science from [Embry-Riddle Aeronautical University](/org/embry-riddle-aeronautical-university) and a Master in Systems Engineering from [University of Florida](/org/university-of-florida).

Their manager is Rady Johnson, EVP, Chief Compliance, Quality & Risk Officer. They are on a team with Sue Diviney - VP, Office of the Ombuds Lead, Carol Bye - VP, Regulatory Quality Assurance, and Lev Kubiak - VP, Chief Security Officer.

Guy Delp

Gautam Gupta is the SVP, Head of Strategy & Consulting at [Pfizer](/org/pfizer). Gautam has over 20 years of experience in the consulting industry. Gautam has worked with some of the largest companies in the world, including The Boston Consulting Group and Booz, Allen and Hamilton. Gautam has a deep understanding of the pharmaceutical industry and has helped [Pfizer](/org/pfizer) to develop and execute its strategy for many years.

Gautam Gupta graduated from the Indian Institute of Management Ahmedabad with an MBA in strategy and finance. Gautam also holds a B.A. (Honours) in economics from St. Stephen's College, Delhi and an AISSCE in economics and mathematics from Delhi Public School - R. K. Puram.

Their manager is Aamir Malik, EVP, Chief Business Innovation Officer. Gautam Gupta works with Bill Leister - SVP, Advanced Analytics/Data Platforms & Learning/Development, Sirsij Peshin - VP, Global Commercial Operations, and Maria Reilly - VP, Global Commercial Operations - North America.

Gautam Gupta

Eileen Cheigh is currently the VP of Business Assessment for the Chief Business Office at [Pfizer](/org/pfizer). Eileen has been with [Pfizer](/org/pfizer) since August 1996 and in their current role since February 2014. Prior to their current role, they were the Senior Director of Global Strategy & Operations for the Established Products Business Unit where they oversaw the development and implementation of [Pfizer](/org/pfizer)'s global generics expansion strategy. This included prioritizing investments across markets, project management of organic and inorganic portfolio expansion, and governance model. Under their leadership, the Established Products Business Unit met global financial targets of $1.2B in 2013 revenues and 41% growth through 2015.

Before joining [Pfizer](/org/pfizer), Eileen held various roles in sales and underwriting for health insurance plans at Aetna from January 1991 to December 1994. In their role as a Sales Analyst / Insurance Underwriter, they were responsible for creating new business proposals and implementation plans for large employer health plans in very competitive West Coast health care benefits markets. Eileen also conducted research, risk assessment, and financial analysis in underwriting new policies.

Eileen Cheigh has an MBA in Health Care Management and Finance from The Wharton School and a BA in Economics and American Studies from [Wesleyan University](/org/wesleyan-university).

A direct report to Eileen Cheigh is and Victor Lau - Senior Director, Business Assessments. They work with Maria Reilly - VP, Global Commercial Operations - North America, Bill Leister - SVP, Advanced Analytics/Data Platforms & Learning/Development, and Aaron Foster - VP, Business Analytics & Insights. Their manager is Aamir Malik, EVP, Chief Business Innovation Officer.

Eileen Cheigh

Nilesh Sahi is the current Director of Portfolio & Decision Analysis at [Pfizer](/org/pfizer). Nilesh has over 10 years of experience in the biotechnology and pharmaceutical industries. Prior to joining [Pfizer](/org/pfizer), Mr. Sahi was a Commercial & Portfolio Planning Manager at REGENXBIO Inc., where they oversaw the development and commercialization of gene therapy products. Before that, they were at Alexion Pharmaceuticals, Inc. as a Strategy & Competitive Insights manager for rare disease products. Mr. Sahi started their career in venture capital at Actin Biomed, LLC and then transitioned to clinical research at [Columbia University Medical Center](/org/columbia-university-medical-center). Nilesh has also done research in the Department of Chemistry at Western Kentucky University. Mr. Sahi has a bachelor's degree in biochemistry from Western Kentucky University and a MBA from [Duke University](/org/duke-university).

Nilesh Sahi has a degree in Biotechnology from [Columbia University](/org/columbia-university) in the City of New York. Nilesh also has an Honors Biology & Chemistry degree from Western Kentucky University.

Nilesh Sahi works with Joel Schrock - Senior Director & Team Lead, Portfolio & Decision Analysis, Maayan Pinhassi - Senior Director & Team Lead, Portfolio & Decision Analysis, and Maggie Tsai - Director, Portfolio & Decision Analysis. Their manager is Li Chen, VP, Head of Portfolio & Decision Analysis.

Nilesh Sahi

Maggie Tsai is currently the Director of Portfolio & Decision Analysis at [Pfizer](/org/pfizer). Maggie has over six years of experience in the pharmaceutical and healthcare industries. Prior to joining [Pfizer](/org/pfizer), Ms. Tsai served as the Senior Manager of Corporate Strategic Innovation at BD from August 2013 to June 2018. In this role, they were responsible for leading BD's corporate strategic planning process and identifying new growth opportunities.

Ms. Tsai began their career in the pharma industry as an intern at BD in 2012, where they worked in strategic marketing. Maggie later joined [Prognos](/org/prognos) as a Business Development Intern in 2011. In this role, they assisted with the development and launch of [Prognos](/org/prognos)' first market intelligence product.

Ms. Tsai graduated from Northern Trust University with a degree in Investment Banking in 2008. Maggie is a Certified Public Accountant (CPA) and a Certified Management Accountant (CMA).

Maggie Tsai has a BA in Economics and Mathematics from [Northwestern University](/org/northwestern-university) and an MBA in Marketing, Finance, and Strategic Management from The University of Chicago Booth School of Business.

They are on a team with Joel Schrock - Senior Director & Team Lead, Portfolio & Decision Analysis, Nilesh Sahi - Director, Portfolio & Decision Analysis, and Maayan Pinhassi - Senior Director & Team Lead, Portfolio & Decision Analysis. Maggie Tsai reports to Li Chen, VP, Head of Portfolio & Decision Analysis.

Maggie Tsai

Maayan Pinhassi is the current Senior Director & Team Lead of Portfolio & Decision Analysis at [Pfizer](/org/pfizer). Maayan has held this position since January of 2017. Prior to that, they were the Director of Strategy and Portfolio Management at Mallinckrodt Pharmaceuticals from November 2015 to January 2017. Before that, they were an Senior Engagement Manager at Campbell Alliance, an inVentiv Health company, from August 2010 to November 2015. In this role, they were responsible for corporate strategy, business development, and commercial support for life sciences companies. Maayan also interned in marketing for the pharmaceutical division of Abbott Laboratories from June 2009 to August 2009 and was a marketing assistant at Neopharm Israel from August 2007 to June 2008. Maayan Pinhassi served as a lieutenant in the Israeli Navy from March 1997 to August 2003.

Maayan Pinhassi has an MBA from The University of Chicago Booth School of Business, with honors in marketing, finance, and entrepreneurship. Maayan also has a B.Sc from [Tel Aviv University](/org/tel-aviv-university), magna cum laude in life and medical sciences.

They work with Maggie Tsai - Director, Portfolio & Decision Analysis, Joel Schrock - Senior Director & Team Lead, Portfolio & Decision Analysis, and Nilesh Sahi - Director, Portfolio & Decision Analysis. Their manager is Li Chen, VP, Head of Portfolio & Decision Analysis.

Maayan Pinhassi

Li Chen is the Vice President, Head of Portfolio & Decision Analysis at [Pfizer](/org/pfizer). Li has over 25 years of experience in the life science industry, having worked as a consultant for [L.E.K. Consulting](/org/l-e-k-consulting) for four years. Her key responsibilities included developing analytical frameworks to solve strategic business issues, conducting market research, and presenting findings to senior management. Li also managed project teams of 2-3 junior associates. Prior to their position at [Pfizer](/org/pfizer), Li Chen was a Consultant at [L.E.K. Consulting](/org/l-e-k-consulting) for four years.

Li Chen has a Masters in Business of Bioscience from [Keck Graduate Institute](/org/keck-graduate-institute) and a Bachelor's in Bioengineering from University of California, Berkeley.

Some individuals on their team include Joel Schrock - Senior Director & Team Lead, Portfolio & Decision Analysis, Maggie Tsai - Director, Portfolio & Decision Analysis, and Nilesh Sahi - Director, Portfolio & Decision Analysis. Their manager is Aamir Malik, EVP, Chief Business Innovation Officer. They are on a team with Maria Reilly - VP, Global Commercial Operations - North America, Jörgen Schaffers - VP, Global Commercial Operations - International Developed Markets, and Aaron Foster - VP, Business Analytics & Insights.

Li Chen

Sirsij Peshin is the current Vice President of Global Commercial Operations at [Pfizer](/org/pfizer). Sirsij has over 25 years of experience in the pharmaceutical and healthcare industry. Prior to joining [Pfizer](/org/pfizer), they were the Business Manager for IT & Corporate Planning at Pharmacia & Upjohn from September 1997 to May 2003. In this role, they were responsible for the India region's IT, strategic planning, and clinical data management. Peshin also has experience as a systems manager and systems officer. Sirsij began their career in sales and marketing at New International Travels from January 1988 to August 1989.

Sirsij Peshin has a degree in Electronics from the University of Kashmir, a Masters in Computer Applications from the [Thapar Institute of Engineering & Technology](/org/thapar-university), and a certification from the National Council for Behavioral Health in Mental Health First Aid USA. Sirsij also has experience in management development and executive leadership from their time at the Indian Institute of Management Ahmedabad and [Pfizer](/org/pfizer).

Their manager is Aamir Malik, EVP, Chief Business Innovation Officer. Sirsij Peshin works with Aaron Foster - VP, Business Analytics & Insights, Mike Sweitzer - VP, Global Commercial Operations - Emerging Markets, and Bill Leister - SVP, Advanced Analytics/Data Platforms & Learning/Development.

Sirsij Peshin

Jason O'Meara is currently the VP of Enterprise Data & Solutions Architecture at [Pfizer](/org/pfizer). Prior to joining [Pfizer](/org/pfizer) in March 2019, Jason was the Senior Director of Architecture at [Quest Diagnostics](/org/quest-diagnostics) from March 2004 to March 2019. In this role, Jason was responsible for overseeing the architectural aspects of [Quest Diagnostics](/org/quest-diagnostics)' healthcare connectivity and enterprise data & analytics solution architectures. Jason led a team of architects in the creation of business solutions that leveraged a number of technologies, including healthcare interoperability & data exchange standards (HL7v2, FHIR, SMART, etc.), blockchain, bioinformatics, cloud-native architectures, microservices & responsive user experiences, Chatbots & NLP, master data management, data warehousing & big data, data visualization & business intelligence, and AI and advanced analytics. Jason also supported architectural aspects of M&A due diligence.

Before [Quest Diagnostics](/org/quest-diagnostics), Jason worked as a Senior Consultant in Information Technology at Cap Gemini Ernst & Young Consulting from August 2000 to March 2004.

Jason O'Meara has a Masters in Health Policy and Administration from the [University of North Carolina at Chapel Hill](/org/university-of-north-carolina-at-chapel-hill) and a BSE in Electrical and Computer Engineering from [Duke University](/org/duke-university).

Their manager is Lidia Fonseca, EVP, Chief Digital & Technology Officer. They are on a team with and Dennis Hancock - SVP, Digital - Customer Experience, Commercial Enablement & Market-facing Solutions.

Jason O'Meara

Dennis Hancock is currently the SVP, Digital - Customer Experience, Commercial Enablement & Market-facing Solutions at [Pfizer](/org/pfizer). Prior to that, they were a Consultant at Productivity Point International from January 1993 to December 1995.

Dennis Hancock graduated from the University of Maryland with a BS in Education.

They are on a team with and Jason O'Meara - VP, Enterprise Data & Solutions Architecture. Their manager is Lidia Fonseca, EVP, Chief Digital & Technology Officer.

Dennis Hancock

Dr. Jeff Settleman is the Senior Vice President, Chief Scientific Officer for Oncology Research and Development and serves as the La Jolla site head. Dr. Settleman leads all oncology research from the beginning stages of discovery to proof of concept clinical studies.

Dr. Settleman is an internationally recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine.

Dr. Settleman held numerous notable positions in both academic research and drug discovery before joining the [Pfizer](/org/pfizer) team. Prior to his current role, Dr. Settleman served as Distinguished Principal Investigator and Head of Oncology Research at [Calico](/org/calico) Life Sciences. Prior to [Calico](/org/calico), Dr. Settleman led Discovery Oncology at [Genentech](/org/genentech).

Dr. Settleman served as a Professor at the Harvard School of Medicine for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology. During that same timeframe, Dr. Settleman served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center.

Dr. Settleman’s impressive career began at the Whitehead Institute for Biomedical Research at MIT where he was a postdoctoral fellow in Oncology and Cancer Biology.

Dr. Settleman received his Ph.D. in Genetics from [Yale University](/org/yale-university) and his B.A. in Neuroscience from the [University of Pennsylvania](/org/university-of-pennsylvania). He is the author of over 240 peer-reviewed publications, many of which have appeared in Cell, Science, and Nature.

Jeff Settleman

Emer has +20 years experience in the pharma industry across manufacturing, engineering, operational excellence and supply chain. Her experience in operational excellence saw her gain extensive experience in value stream improvement of global products, project coaching, training delivery and support for lean transformation. Furthermore, in product portfolio management she was responsible for strategic supply chain design and identified and executed cross-functional, strategic projects.

Emer Cunningham

Joan Campion is currently the VP of Commercial Communications at [Pfizer](/org/pfizer). Joan has been with the company since October 2007 and previously held the title of Senior Director. Prior to their time at [Pfizer](/org/pfizer), Campion worked for Alcatel-Lucent from December 1997 to April 2007. During their time there, they held the position of Director.

Joan Campion has a BA from [Columbia University](/org/columbia-university) in the City of New York.

They work with and Vanessa McGowan - VP, Global Enterprise Communications. Joan Campion reports to Sally Susman, EVP, Chief Corporate Affairs Officer.

Joan Campion

Sheila Brodbeck is the SVP, Chief Litigation Counsel at [Pfizer](/org/pfizer). Sheila was previously a litigation associate at Simpson Thacher & Bartlett LLP from September 1998 to December 2008.

Sheila Brodbeck received their Doctor of Law (J.D.) from the University of Virginia School of Law and their Bachelor of Arts (B.A.) in English Language and Literature, General from [Princeton University](/org/princeton).

Sheila Brodbeck reports to Doug Lankler, EVP, General Counsel. Some of their coworkers include Eric Aaronson - SVP, Chief Counsel - Corporate Affairs, IP & IP Enforcement, Bryan Supran - SVP, Deputy General Counsel.

Sheila Brodbeck

Kendra K. Bence is currently the Executive Director of Metabolism at [Pfizer](/org/pfizer). Kendra has previous experience as an Associate Professor at the [University of Pennsylvania](/org/university-of-pennsylvania) from January 2006 to December 2015, and as a Post-doctoral fellow at Beth Israel Deaconess Medical Center from January 2000 to December 2005.

Kendra K. Bence has a Ph.D. in Physiology and Biophysics from Weill Cornell Graduate School of Medical Sciences, and a B.A. in Biology from [Colgate University](/org/colgate-university).

They are on a team with and Bei B Zhang - VP, Metabolic Research. Their manager is William C. Sessa, SVP, Chief Scientific Officer - Internal Medicine Research Unit.

Kendra K. Bence

Joel Schrock is currently the Senior Director & Team Lead of Portfolio & Decision Analysis at [Pfizer](/org/pfizer). Prior to their current position, Joel was a Fund Manager at Big Red Ventures from September 2014 to May 2015. In this role, Joel was responsible for deal sourcing, leading due diligence teams, negotiating term sheets, making investments, and managing fund operations. 

Before their time at Big Red Ventures, Joel was a Founding Member and Board Advisor of the Bench to Bedside Initiative from January 2011 to May 2015. The Bench to Bedside Initiative is a student-run organization that aims to bridge the gap between laboratory research and clinical medicine. 

Joel has also been a Graduate Teaching Assistant at Weill Cornell Medical College from November 2010 to January 2013, where they taught undergraduate students about cancer biology. In addition, Joel was a Graduate Student Researcher at Memorial Sloan-Kettering Cancer Center from June 2009 to May 2014, where they conducted research on the genetic basis of cancer. 

Joel earned their BS in Biology from [Cornell University](/org/cornell-university) in 2009 and their PhD in Genetics & Development from Weill Cornell Medical College in 2014.

Joel Schrock received their Master of Business Administration (M.B.A.) from Cornell Johnson Graduate School of Management. Joel went on to earn their Doctor of Philosophy (Ph.D.) in Pharmacology from Joan & Sanford I. Weill Medical College of [Cornell University](/org/cornell-university). Finally, they completed their Bachelor of Arts (B.A.) in Chemistry from [Luther College](/org/luther-college).

Joel Schrock reports to Li Chen, VP, Head of Portfolio & Decision Analysis. Joel Schrock works with Maggie Tsai - Director, Portfolio & Decision Analysis, Maayan Pinhassi - Senior Director & Team Lead, Portfolio & Decision Analysis, and Nilesh Sahi - Director, Portfolio & Decision Analysis.

Joel Schrock

Aaron Foster is currently the VP of Business Analytics & Insights at [Pfizer](/org/pfizer). Aaron has previous experience working as a manager for Economic Consulting Services at [KPMG](/org/kpmg) from April 2000 to November 2003. Additionally, they interned as a statistician in the Biostatistics Division at [Bristol-Myers Squibb](/org/bristol-myers-squibb) from June 1996 to September 1996.

Aaron Foster has a Doctor of Science in Biostatistics from [Harvard University](/org/harvard) and a Bachelor of Science in Mathematics from [Morehouse College](/org/morehouse-college).

They are on a team with Mike Sweitzer - VP, Global Commercial Operations - Emerging Markets, Jörgen Schaffers - VP, Global Commercial Operations - International Developed Markets, and Maria Reilly - VP, Global Commercial Operations - North America. Aaron Foster reports to Aamir Malik, EVP, Chief Business Innovation Officer.

Aaron Foster

Domenica Askeland is aVP, [Global Business Services](/org/global-business-services) - Colleague Services at [Pfizer](/org/pfizer). Domenica previously worked at Coopers & Lybrand LLP as an auditor.

Domenica Askeland has a Bachelor of Science in Accounting from [Boston College](/org/boston-college).

They work with Erik Meader - VP, Global Sourcing Operations & Enablement, Samuel Dowell - VP, Global Procurement. Domenica Askeland reports to Bill Carapezzi, EVP, [Global Business Services](/org/global-business-services) & Transformation.

Domenica Askeland

Erik Meader has over 25 years of experience in global sourcing, procurement and operations. Erik is currently the Vice President of Global Sourcing Operations & Enablement at [Pfizer](/org/pfizer). 

Erik started their career as an Operations Research Analyst at Marathon Oil Corporation. Erik then transitioned to Ford Motor Company as a Buyer. In 1996, they moved to [Campbell Soup Company](/org/campbell-soup-company) as Manager - Purchasing. After two years in that role, Erik became a Consultant at PricewaterhouseCoopers. 

In 2000, Erik joined ShareMax as Director of Operations. Erik stayed with the company for just over a year before joining [Pfizer](/org/pfizer) in 2001 as Director, Global Procurement. Erik held this role for five years before being promoted to Senior Director, Global Procurement, a position they held for twelve years until their current role. 

In addition to their work at [Pfizer](/org/pfizer), Erik has also been an Adjunct Professor at the [University of Delaware](/org/university-of-delaware) and [Wilmington University](/org/wilmington-university).

Erik Meader has a Ph.D. in Organizational Leadership with a Business Concentration from [Eastern University](/org/eastern-university), an MBA in Finance from the University of Pittsburgh - Joseph M. Katz Graduate School of Business, and a BS in Industrial Engineering from [Penn State University](/org/penn-state).

Their manager is Bill Carapezzi, EVP, Global Business Services & Transformation. They work with Domenica Askeland - VP, Global Business Services - Colleague Services, Samuel Dowell - VP, Global Procurement.

Erik Meader

Bill Leister has been working in the field of analytics and data platforms for over 20 years. Bill started their career at [LabCorp](/org/labcorp), where they worked their way up to becoming the Chief Architect and VP of Informatics. In 2012, they left [LabCorp](/org/labcorp) to join Premier, Inc. as their Principal Technical Architect. Mr. Leister was responsible for implementing Premier’s new integrated performance platform. In 2014, they left Premier to join [Quest Diagnostics](/org/quest-diagnostics) as their VP Informatics, Analytics & Business Intelligence. Bill spent the next five years at [Quest Diagnostics](/org/quest-diagnostics), leading Product Management, Business Analysis, Informatics and Analytic teams. In July 2019, they returned to [Pfizer](/org/pfizer) as their Senior Vice President, Advanced Analytics and Data Platforms & Learning and Development. Bill is currently still employed at [Pfizer](/org/pfizer) in this role.

Bill Leister's educational career includes a BS in Management Information Systems from North Carolina State University - College of Management.

Their manager is Aamir Malik, EVP, Chief Business Innovation Officer. They are on a team with Sirsij Peshin - VP, Global Commercial Operations, Aaron Foster - VP, Business Analytics & Insights, and Maria Reilly - VP, Global Commercial Operations - North America.

Bill Leister

Bryan Supran is the SVP, Deputy General Counsel at [Pfizer](/org/pfizer). Bryan has over 25 years of experience as a life sciences attorney, specializing in corporate and securities law. Bryan has also served as an associate at Ropes & Gray LLP.

Bryan Supran received their JD from New York University School of Law and their A.B. in Politics / East Asian Studies from [Princeton University](/org/princeton).

Bryan Supran reports to Doug Lankler, EVP, General Counsel. Some of their coworkers include Sheila Brodbeck - SVP, Chief Litigation Counsel, Eric Aaronson - SVP, Chief Counsel - Corporate Affairs, IP & IP Enforcement.

Bryan Supran

Dave Binder is the current VP of Talent & Organizational Effectiveness at [Pfizer](/org/pfizer). Dave has over 20 years of experience in HR and management, having worked previously as an Executive Director of Talent Management at [Morgan Stanley](/org/morgan-stanley) and a Vice President of HR Development at JP Morgan Chase. Dave has been instrumental in facilitating successful outcomes for several challenging and high profile merger integration efforts. Dave is a senior management development consultant and has a passion for organizational development and employee learning.

Dave Binder has a Ph.D. in Industrial and Organizational Psychology from [The Ohio State University](/org/the-ohio-state-university). Dave also has a Bachelor's degree in Psychology from [Stony Brook University](/org/stony-brook-university).

Dave Binder works with and Steve First - VP, [Global Benefits](/org/global-benefits). Dave Binder reports to Payal Sahni, EVP, CHRO.

Dave Binder

Brian Byala is currently the SVP, Treasurer at [Pfizer](/org/pfizer). Brian has over 20 years of experience in the pharmaceutical industry, having previously worked as the Sr VP and Treasurer at Mylan Pharmaceuticals and Mylan Inc. from 2007 to 2013. Prior to that, they worked at [Pfizer](/org/pfizer), Inc. from 1994 to 2007, where they held the position of Assistant Treasurer.

Brian Byala received their MBA from the Cornell Johnson Graduate School of Management.

Some of their coworkers include and Emer Cunningham - VP, Internal Medicine Global Supply Chain. Brian Byala reports to David M. Denton, EVP, CFO.

Brian Byala

Vanessa McGowan is the VP of Global Enterprise Communications at [Pfizer](/org/pfizer). Vanessa has been with the company since 1998 and in their current role since 2006.

Vanessa McGowan has a Master of Science in Public Relations and Corporate Communications from [New York University](/org/nyu) and a Bachelor’s Degree from [New York Institute of Technology](/org/new-york-institute-of-technology).

They work with and Joan Campion - VP, Commercial Communications. Their manager is Sally Susman, EVP, Chief Corporate Affairs Officer.

Vanessa McGowan

Samuel Dowell is currently the Vice President of Global Procurement at [Pfizer](/org/pfizer). Samuel has held this position since January 1998. Prior to that, they were the Senior Buyer and Supply Chain Analyst at Ford Motor Company from January 1992 to December 1998. Samuel also served as a Lieutenant Commander in the U.S. Navy Reserve from January 1991 to December 2001.

Samuel Dowell has a Bachelor of Business Administration from the [University of Notre Dame](/org/university-of-notre-dame) and a Master of Business Administration from Ball State University - Miller College of Business.

They are on a team with Erik Meader - VP, Global Sourcing Operations & Enablement, Domenica Askeland - VP, Global Business Services - Colleague Services. Samuel Dowell reports to Bill Carapezzi, EVP, Global Business Services & Transformation.

Samuel Dowell

Professor of Neuroscience and President Emerita at the Massachusetts Institute of Technology (MIT). Served as MIT’s sixteenth president from 2004 to 2012 and was the first woman and the first life scientist to lead MIT. Member of the Koch Institute for Integrative Cancer Research at MIT. Prior to joining MIT, she was the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences from 1998 to 2002 and Provost from 2003 to 2004 at [Yale University](/org/yale-university). Served as Science Envoy with the [U.S. Department of State](/org/department-of-state) and as a member of a Congressional Commission evaluating the [Department of Energy](/org/department-of-energy) laboratories. Director of General Electric Company from 2006 until 2018 and of [Qualcomm](/org/qualcomm) from 2012 to 2016. [Pfizer](/org/pfizer) Director since 2020. Member of the Regulatory and Compliance and Science and Technology Committees.

Susan Hockfield

Megan Briggs

Matthew Toth

Bob Aucker

Donna Cox

Emily Ruchty

John Berry

Antoine Turcotte

Jason Lynn

Clarence Manuel

Eugenia Baek

Maureen Nail

Sagar Visaria

Pauline Wright

Chairman of the [Thomson Reuters Foundation](/org/thomson-reuters-foundation), a London-based charity supported by the global news and information provider. President, Chief Executive Officer and Director of Thomson Reuters Corporation, a provider of intelligent information for businesses and professionals, from 2012 until his retirement in 2020. He also served as its Chief Operating Officer from September 2011 to December 2011 and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning's Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. Director of [Refinitiv](/org/refinitiv), a privately-held global provider of financial market data and infrastructure until its acquisition by the London Stock Exchange Group in 2021. [Pfizer](/org/pfizer) Director since 2014. Chair of the Compensation Committee and Member of the Audit Committee.

James C. Smith

Founder, Managing Partner of Gennx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching Gennx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. Also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of Advantage Solutions Inc., CarMax, Inc., and W.R. Berkley, Inc., an insurance holding company. Director of Urban One, Inc. from 2002 to 2019. Director of Syncreon U.S., a for-profit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of [New York University](/org/nyu) Stern School of Business. [Pfizer](/org/pfizer) Director since 2017. Member of the Compensation and Audit Committees.

Ronald E. Blaylock

Investigator, the [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute) since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the [National Academy of Sciences](/org/national-academy-of-sciences) in 2007. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize. Received: the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences (2015); the Passano Award (2016); the Harrington Prize for Innovation in Medicine (2018); the Lefoulon-Delalande Grand Prize in Science (2018); the Gerald D Aurbach Award for Outstanding Translational Research (2019); and the Anitschkow Prize (2019). [Pfizer](/org/pfizer) Director since 2011. Chair of the Science and Technology Committee and Member of the Governance & Sustainability and Regulatory and Compliance Committees.

Helen H. Hobbs

Chief Executive Officer of [Deloitte](/org/deloitte) LLP (Deloitte), a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with [Deloitte](/org/deloitte), served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporation, Unum Group, a provider of financial protection benefits, and Xerox Corporation. Former member of the President's Export Council and former member of the Presidential Commission on Election Administration. Former Chair of My Brother's Keeper Alliance. Special Advisor to the President of [University of Miami](/org/university-of-miami) and Member of the Board of Trustees of the [University of Miami](/org/university-of-miami). [Pfizer](/org/pfizer) Director since 2015. Chair of the Governance & Sustainability Committee and Member of the Audit Committee.

Joseph J. Echevarria

Chairman, President and Chief Executive Officer of Adobe Inc. (Adobe), a producer of creative and digital marketing software. Prior to his appointment as CEO in 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development.

President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world. Vice Chairman of US-India Strategic Partnership Forum. Consistently named one of the world's best CEOs by [Barron's](/org/barrons) magazine and, in 2020, ranked as a Fortune “Business Person of the Year.” [Pfizer](/org/pfizer) Director since 2013. He is the Lead Independent Director.

Shantanu Narayen

Retired Vice Chairman, [Goldman Sachs](/org/goldman-sachs) Group, Inc. (Goldman Sachs), since 2007. During her 21-year tenure with [Goldman Sachs](/org/goldman-sachs), served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Director of Intuit Inc. and Visa Inc. Co-Chair, Board of Trustees of The Brookings Institution; Co- Chair of the Board of Trustees of the Carnegie Institution of Washington and Co- Chair of the Investment Committee of the Board of Trustees of the [University of Southern California](/org/university-of-southern-california). Director of American International Group, Inc. from 2008 to 2020. [Pfizer](/org/pfizer) Director since 2007. Chair of the Audit Committee and Member of the Regulatory and Compliance Committee.

Suzanne Nora Johnson

As Chairman and Chief Executive Officer, Albert Bourla leads [Pfizer](/org/pfizer) in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 25 years at [Pfizer](/org/pfizer), Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the [Pfizer](/org/pfizer)’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.

Previously, from February 2016 to December 2017, Albert served as Group President of [Pfizer](/org/pfizer) Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of [Pfizer](/org/pfizer)’s medicines, and ensuring broader business model innovation.

From January 2014 to January 2016, Albert served as Group President of [Pfizer](/org/pfizer)’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.

Albert was President and General Manager of [Pfizer](/org/pfizer)’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to [Pfizer](/org/pfizer)’s off-patent portfolio, (including legacy brands and generics).

He began his [Pfizer](/org/pfizer) career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to [Pfizer](/org/pfizer)’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a vice president of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards – [Pfizer](/org/pfizer), Inc., The [Pfizer](/org/pfizer) Foundation, PhRMA, and Catalyst – and a trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.

Albert Bourla

Sally Susman is Executive Vice President and Chief Corporate Affairs Officer at [Pfizer](/org/pfizer). She chairs [Pfizer](/org/pfizer)'s Political Action Committee and is vice chair of the [Pfizer](/org/pfizer) Foundation.

Sally directs [Pfizer](/org/pfizer)'s global communications and its public affairs activities, including high-level relations with the governments of all nations in which the Company has operations or markets products. Sally also heads the firm's corporate responsibility group and plays a key role in shaping the Company's policy initiatives. Before joining [Pfizer](/org/pfizer) in 2007, Sally held roles at Estée Lauder Companies and the American Express Company. Earlier in her career, she spent eight years in government service focused on international trade issues.

Sally serves on the board of WPP plc, a world leader in advertising and marketing based in the U.K., and as co-chair of the board of The International Rescue Committee.

Sally Susman

Angela Hwang is a member of [Pfizer](/org/pfizer)’s Executive Team and Group President of the [Pfizer](/org/pfizer) Biopharmaceuticals Group, which comprises 80% of [Pfizer](/org/pfizer)’s revenues. Her organization of 26,000 colleagues is responsible for bringing over 600 innovative medicines and products to patients. In 2019, more than 434 million people benefited from a [Pfizer](/org/pfizer) Biopharma medicine or vaccine to improve their health and, in some cases, save their lives. Altogether, [Pfizer](/org/pfizer) Biopharma generated around $40 billion in 2019 revenues.

As Group President of [Pfizer](/org/pfizer) Biopharma, Angela leads 7 commercial business units, reaching patients in more than 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.

Angela has been with [Pfizer](/org/pfizer) for 23 years, working across all geographies and therapeutic areas. She is motivated by the common purpose that all [Pfizer](/org/pfizer) colleagues share, to bring breakthroughs to patients, regardless of where they are in the world. Her childhood as an Asian girl growing up in apartheid South Africa, defined her worldview and underscored the importance of equity in everything she does today.

Angela sits on the boards of EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the [Pfizer](/org/pfizer) Foundation, a charitable organization that addresses global health challenges. She has also been active in industry groups such as BIO, where she previously co-chaired the Vaccines Policy Committee. In 2019, she was named in Crain’s Notable Women in Healthcare list.

Having always been curious about transformation and the art of the possible, in 2019, Angela launched Diverse Perspectives, a podcast series where she hosts global thought leaders pioneering change across a variety of industries. You can learn more about Diverse Perspectives here, and subscribe on iTunes, Spotify, and other streaming platforms.

Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and MBA from Cornell University.

Angela Hwang

Doug Lankler joined [Pfizer](/org/pfizer) in 1999 and currently serves as general counsel. Prior to being named general counsel, Doug was [Pfizer](/org/pfizer)'s chief compliance and risk officer, a role he assumed in 2006.

Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the United States Attorney General's Distinguished Service Award.

Doug graduated from the State University of New York at Albany and Cornell Law School.

Doug Lankler

Bill Carapezzi is Executive Vice President, Global Business Services and Transformation, responsible for global procurement, global financial shared services, human resources operations, real estate, and the financial project management office, as well as for elements of commercial operations.

Previously, Bill was Senior Vice President of Global Business Operations. In this role, Bill led global financial solutions, procurement, workplace solutions, tax, insurance and the financial portfolio management office. Bill joined [Pfizer](/org/pfizer) in March 2008 as the Senior Vice President of Global Tax.

Prior to joining [Pfizer](/org/pfizer), Bill was with Lucent Technologies, Inc., for 18 years in a variety of roles including Executive Vice President & General Counsel and Vice President of Treasury & Tax. In addition, Bill spent six years in public accounting at Arthur Andersen & Co.

Bill holds a Bachelor of Science degree in Accounting from [Fairfield University](/org/fairfield-university), a Juris Doctor (JD) from Western New England School of Law, and a LL.M in Taxation from New York University School of Law. He is also a Certified Public Accountant.

Bill Carapezzi

Payal Sahni is Executive Vice President, Chief Human Resources Officer, responsible for [Pfizer](/org/pfizer)’s global talent strategy, diversity and inclusion, total rewards and colleague experience.

In her prior role, Payal was the Senior Vice President, Human Resources, for [Pfizer](/org/pfizer) Biopharmaceuticals Group, leading the HR strategy for seven business units, as well as for the Corporate Affairs, Legal, Compliance and Chief Business Office functions.

Payal joined [Pfizer](/org/pfizer) Human Resources in 1997. Since then, she has held a number of Regional and Global HR Business Partner roles supporting the business around the world and has led the Talent Organization for [Pfizer](/org/pfizer) Global Supply. In addition, Payal has spearheaded numerous transformations as [Pfizer](/org/pfizer) evolved its business structure and has been instrumental in managing HR strategy for several mergers and acquisitions.

Payal holds a Bachelor of Arts in Psychology from [Rider University](/org/rider-university) and a Master of Arts in Psychology from [Fairleigh Dickinson University](/org/fairleigh-dickinson-university).

Payal Sahni

Gregory LaRosa, Ph.D., is Vice President and Head of Scientific Research. Greg is responsible for RDRU portfolio strategies including external plans and monitoring the pre-clinical and clinical project progression. Greg received a Ph.D. from [Harvard University](/org/harvard) (Division of Medical Sciences) in Molecular, Cellular, and Developmental Biology, and has 30 years of experience in rare disease and inflammation drug discovery and development.

Prior to joining [Pfizer](/org/pfizer) in July 2012, Greg worked in several start-up and midsize biotechnology companies, most recently serving as President and CSO at BIKAM Pharmaceuticals, Inc., Cambridge, MA. At BIKAM, Greg led the internal team charged with the discovery and validation of novel small molecule pharmacologic chaperones for the rod cell visual pigment, with the goal to correct the misfolding and trafficking of mutant rhodopsin that causes Retinitis Pigmentosa.

From 2003 until 2008, Greg served as Vice President of Discovery Research at Critical Therapeutics, Inc., Lexington, MA, leading a group of biologists and chemists focusing largely on the pre-clinical validation of the concept that alpha-7 nAChR modulators could have broad use as anti-inflammatory therapeutics. He worked to discover and begin the development of novel anti-inflammatory, peripherally acting, compounds that target alpha-7, and demonstrated efficacy in animal models of inflammatory and allergic disease.

Before Critical Therapeutics, Greg served as Senior Director of Immunopharmacology at Millennium Pharmaceuticals, Inc., from 1999 to 2003, where his work was focused on several inflammation drug discovery projects targeting chemokine receptors, adhesion proteins, and kinases. From September 1994 to December 1999 he served in several senior research positions at LeukoSite, Inc., a biotechnology company focused on chemokines, adhesion proteins and inflammation drug discovery. From 1988 to September 1994, Greg held several research posts at [Repligen](/org/repligen), Corp., a biotechnology company in the Boston area.

Greg Larosa

Christos Kelektsoglou

Marie-Pierre Hellio Le Graverand

William Pao, M.D., Ph.D. is Chief Development Officer and Executive Vice President for [Pfizer](/org/pfizer). William leads the Global Product Development organization, which is responsible for the clinical development and advancement of [Pfizer](/org/pfizer)’s pipeline of innovative medicines in inflammation and immunology, internal medicine, hospital, oncology and rare disease, as well as regulatory affairs in support of [Pfizer](/org/pfizer)’s R&D pipeline and portfolio of marketed therapies. 

Prior to joining [Pfizer](/org/pfizer) in 2022, William served as the Head of Roche Pharma Research & Early Development (pRED), where he oversaw the discovery and early development of a portfolio of new molecular entities to treat diseases related to cancer, neuroscience, ophthalmology, rare diseases, immunology, infectious diseases, and rare blood disorders, across seven global sites. He was also a member of Roche’s Enlarged Corporate Executive Committee.

Before joining Roche, he simultaneously held key positions of Professor of Medicine and Director of the Division of Hematology/Oncology at [Vanderbilt University](/org/vanderbilt-university), and Director of Personalized Cancer Medicine at Vanderbilt-Ingram Cancer Center.

William is recognized for his ground-breaking work in translational medicine, mechanistic and clinical studies of targeted cancer therapeutics, and for his leadership in cancer genomics and personalized medicine. His laboratory work identiﬁed new molecular mechanisms of sensitivity and resistance of lung cancers to EGFR tyrosine kinase inhibitors (TKIs), yielded important insights into a molecular understanding of lung cancer and other malignancies, and led to the development of multiple therapeutics to treat lung cancer. The author of multiple scientiﬁc and medical publications, William has served as an advisor to numerous professional associations including the [National Cancer Institute](/org/national-cancer-institute) (NCI), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) and has served on the editorial boards of prestigious medical research journals including Cancer Discovery, Cancer Research, Clinical Cancer Research, and the Journal of Clinical Oncology. William also co-founded MyCancerGenome, an internationally recognized online tool to enable a genetically informed approach to cancer medicine. He currently serves as co-chair of the Executive Committee of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership. He was elected to the American Society for Clinical Investigation in 2011 and the Association of American Physicians in 2017.

William received his undergraduate degree from Harvard, and his M.D. and Ph.D. degrees from Yale University. Following his residency training in Internal Medicine at New York-Presbyterian Hospital/Weill-Cornell Medical School Campus, he completed his medical oncology and postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center, going on to become a member of the faculty at that institution.

William Pao

William C. Sessa is currently Senior Vice President and Chief Scientific Officer for the Internal Medicine Research Unit at Pfizer, located in Cambridge, MA. In this role, Dr. Sessa leads the discovery of novel transformative therapies to potentially treat or prevent cardiometabolic diseases, which represent some of the world’s most significant health challenges. He is responsible for guiding the portfolio and technology strategies to bring programs from discovery through to proof of concept in the clinic.

Dr. Sessa joined Pfizer in 2022 after a nearly 30-year career as a research scientist at Yale University, leading an academic laboratory focused on vascular biology. At Yale, he served as the Alfred Gilman Professor and Vice Chairman in the Department of Pharmacology and as Director of the Vascular Biology & Therapeutics Program at Yale School of Medicine. Dr. Sessa earned his Bachelor of Science in Pharmacy from Philadelphia College of Pharmacy & Sciences; his Master of Science in Pharmacology and Toxicology from the University of Rhode Island; and his Ph.D. in Pharmacology from New York Medical College, before completing post-doctoral fellowships at The William Harvey Research Institute and The University of Virginia Health Sciences Center.

William C. Sessa

Dr. Bei B. Zhang is a seasoned pharmaceutical executive and a proven leader. She is currently Vice President at Pfizer Worldwide Research, Development & Medical in Cambridge, MA. She is leading research from setting strategy to advancing projects in the pipeline in multiple disease areas including cancer cachexia, cardiometabolism/HF, PAH, and metabolic disorders. Dr. Zhang is also leading state-of-the-art technology omics platforms to enable innovation and discovery.

During 2010 – 2017, Dr. Zhang was Vice President at Lilly and the founding General Manager and Site Head/SVP of the Lilly China Research and Development Center (LCRDC) in Shanghai. As part of the efforts to develop strategic vision and overall research strategy, Dr. Zhang built a talented research team of over 100 scientists and staff, a pipeline of innovative drug candidates in NASH/fibrosis and metabolic diseases, and a strong and sustainable R&D infrastructure. In a period of few years and building from ground zero, the team advanced programs in the pipeline with multiple candidates for development.

Prior to joining Lilly, Dr. Zhang was the Franchise Site Lead of diabetes discovery research in Merck Research Laboratories in Rahway, New Jersey. Dr. Zhang played a key role in the discovery, development and launches of sitagliptin (JANUVIA®) as a novel blockbuster for diabetes in the US, China, Japan and Korea. She led teams to bring numerous drug candidates from the laboratory to clinical testing and human proof-of-concept during her tenure at Merck.

Dr. Zhang has an excellent track record of scientific accomplishment illustrated by lectures at numerous scientific conferences and over 140 original articles in peer-reviewed scientific journals. She is regarded as a leading expert in the field and in pharmaceutical research and development. Dr. Zhang was elected to the Scientific Advisory Board of Keystone Symposia in 2011 and the Board of Directors of Keystone Symposia on Molecular and Cellular Biology in 2013

Dr. Zhang worked closely with the Lilly Asia Venture (LAV) for more than 5 years and was on the investment committee of LAV. She is well connected in the scientific community in the US and Europe as well as China and Asia Pacific where her network encompasses VC, Biotech and academic communities around the world.

Dr. Zhang received her Ph.D. (Indiana U) and postdoctoral fellowship (Stanford U). She is a graduate of Harvard Business School AMP.

Bei B Zhang

Lauren Ferschman

Ken Rhodes, PhD, is Vice President, Rare Neurology and Discovery Biology in Pfizer’s Rare Disease Research Unit. In this role, he is responsible for guiding drug discovery programs that seek to improve the lives of patients suffering from rare neurological diseases as well as research activities supporting all therapeutic areas within the Rare Disease Research Unit.

Ken earned his BA in Psychology at Williams College and PhD in Anatomy, studying with Dr. Douglas Rosene in the Department of Anatomy and Neurobiology at Boston University. Ken did postdoctoral training in systems neuroscience with Dr. Michael E. Goldberg at the National Eye Institute, National Institutes of Health, and in neuropharmacology with Dr. David Farb at the Boston University School of Medicine.

Over the past 28 years, Ken has held a series of executive leadership positions in pharmaceutical and biotechnology discovery research, working across therapeutic modalities to identify and advance therapeutic candidates for the treatment of central nervous system diseases. Prior to joining Pfizer, Ken was Senior Vice President, Therapeutics Discovery, at Wave Life Sciences, responsible for development of oligonucleotide therapeutics for neurologic and other diseases.

From 2014-2020, Ken was co-founder and Chief Scientific Officer at Yumanity Therapeutics, where he built and led a team focused on the elucidation of novel pathways and drug targets for neurodegenerative diseases. Ken’s team made the seminal discovery that inhibitors of fatty acid biosynthesis, specifically, inhibitors of the enzyme stearoyl-CoA-desaturase (SCD), protect cells from toxicity caused by a-synuclein, a key genetic risk factor for Parkinson’s disease. This discovery led to the progression of a novel small molecule SCD inhibitor, YTX-7739, into clinical development for the treatment of Parkinson’s Disease.

From 2007-2014, Ken was Vice President, Neurology Discovery, at Biogen. At Biogen, Ken led a discovery research team that delivered nine drug candidates into preclinical and clinical development for the treatment of neurological diseases including multiple sclerosis, Parkinson’s Disease and Alzheimer’s disease. Among these candidates was aducanumab (BIIB-037; Aduhelm), which received FDA approval in 2021 for the treatment of Alzheimer’s disease.

Prior to 2007, Ken held discovery research positions of increasing responsibility, first at Wyeth (now Pfizer), where he lead a team focused on discovery of novel ion channel modulators for the treatment of neurologic disease, then at Johnson & Johnson Pharmaceutical Research and Development (now Janssen) where he built and lead a team focused on drugs to treat Alzheimer’s disease, Parkinson’s disease and ischemic stroke.

Ken Rhodes

Kristen Conway

Jörgen Schaffers was born in Germany and educated as a pharmacist. Jörgen began their pharmaceutical career in 1987 as a medical representative for Warner Lambert/Rhône Poulenc/Bristol. In 1991, they became a product manager for GlaxoWellcome. In 1999, they moved to Warner Lambert as a business unit manager. In 2000, they joined [Pfizer](/org/pfizer) as vice president of global commercial operations for the international developed markets. Jörgen has been with [Pfizer](/org/pfizer) ever since, and is currently the vice president of global commercial operations for the international developed markets.

Jörgen Schaffers studied physical education at KU Leuven and Sint Gabriël college.

Jörgen Schaffers reports to Aamir Malik, EVP, Chief Business Innovation Officer. Jörgen Schaffers works with Eileen Cheigh - VP, Business Assessment - Chief Business Office, Sirsij Peshin - VP, Global Commercial Operations, and Li Chen - VP, Head of Portfolio & Decision Analysis.

Jörgen Schaffers

Maria Reilly

Victor Lau is currently the Senior Director of Business Assessments at [Pfizer](/org/pfizer). Victor has worked at [Pfizer](/org/pfizer) in various capacities for the past few years, including as the Senior Director of Strategy and New Business Assessment from July 2018 to December 2018, and as the Director of Strategy and New Business Assessment from April 2017 to June 2018. Prior to their time at [Pfizer](/org/pfizer), Lau worked at Daiichi Sankyo, Inc. for over 7 years in positions such as Director of Business Development and New Product Planning, Senior Manager of New Business Planning and Business Development, and Manager of Finance Business Development. Lau began their professional career as an Equity Analyst for Wachovia, A Wells Fargo Company, where they worked from September 2001 to October 2007.

Victor Lau has an MBA in finance from [Fordham University](/org/fordham-university).

Victor Lau reports to Eileen Cheigh, VP, Business Assessment - Chief Business Office.

Victor Lau

Pierre Gaudreault is the current President of the Asia Region for the Biopharmaceuticals Group at [Pfizer](/org/pfizer). Prior to this, they served as the General Manager for Pharmascience Canada from August 2012 to July 2014. From July 2014 to June 2016, they were the Chief Marketing Officer for [Pfizer](/org/pfizer) China. In their most recent role before becoming President of the Asia Region, they served as the Country Head for Japan from September 2017 to December 2018.

Pierre Gaudreault is a biologist who specializes in the field of science. Pierre received their education from [Université Laval](/org/universite-laval).

Pierre Gaudreault reports to Angela Hwang, Group President, [Pfizer](/org/pfizer) Biopharmaceuticals Group. Some of their coworkers include and Nanette Cocero - Global President, Vaccines - [Pfizer](/org/pfizer) Biopharmaceuticals Group.

Pierre Gaudreault

Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center since 1995 and an Investigator of the [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute) since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995. Member of the national Academy of the Sciences and the Institute of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of [Vedanta Biosciences](/org/vedanta-biosciences). Advisory Board Member of Immunai, Inc. Member of Scientific Advisory Boards at ChemoCentryx, Inc., the Cancer Research Institute and the Ragon Institute of MGH, MIT and Harvard. Awarded the New York City Mayor's Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013) and the Vilcek Prize in Biomedical Science (2016). [Pfizer](/org/pfizer) Director since 2018. Member of the Governance & Sustainability, Regulatory and Compliance and Science and Technology Committees.

Dan R. Littman

Nicholas Kitchin is Senior Director in Pfizer’s Vaccine Clinical Research and Development group. Dr. Kitchin joined Pfizer in 2011, and currently provides global medical leadership for clinical trials of the company’s investigational Clostridium difficile vaccine. Dr. Kitchin obtained his medical degree from the University of London in 1991 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. After initial training in anaesthesiology, Dr. Kitchin joined the pharmaceutical industry in 1994, and since 1998 has specialized in the field of vaccines. Having had a wide variety of roles in this area, he is a passionate advocate for the public health benefits of vaccination.



Nicholas Kitchin

Dr. Gruber is Senior Vice President of Pfizer Vaccine Clinical Research and Development, and is responsible for global clinical development of vaccines. He joined in 1999 as Vice President of Clinical Vaccine Research for Wyeth, now a wholly owned subsidiary of Pfizer. Prior to his position at Wyeth, Dr. Gruber was an Associate Professor of Pediatrics in the Division of Pediatric Infectious Diseases, Vanderbilt University School of Medicine. He also served as the Director of the Diagnostic Virology Laboratory at Vanderbilt University Hospital.

Dr. Gruber is Board Certified in Pediatrics and Pediatric Infectious Diseases.  He is a Fellow of the American Academy of Pediatrics, member of the  Society for Pediatric Research, Fellow of the Infectious Diseases Society of America, and member of the America Society for Microbiology.  Dr. Gruber has served as a consultant reviewer for the National Institutes of Health, NIAID, the Bill and Melinda Gates Foundation, and PATH.  Consulting activities have included advice on strategies for maternal and infant immunization against RSV and influenza, as well as strategies for prevention of malaria.

Dr. Gruber received his bachelor degree in Mathematical Sciences from Rice University, Houston, Texas, and his medical degree from Baylor College of Medicine, Houston, Texas.  He received his pediatric and infectious disease training at Baylor College of Medicine, where he also served as Chief Resident in Pediatrics.

During his industry career, Dr. Gruber’s clinical research group has been responsible for global clinical development of pneumococcal conjugate, meningococcal conjugate, rLP2086 meningococcal B, Staph aureus, C. difficile, HIV, influenza, RSV, parainfluenza, and HSV vaccines.  Dr Gruber is responsible for guiding clinical research direction for Pfizer’s Group B streptococcus, CMV, and RSV maternal and adolescent vaccine programs.  Dr. Gruber has authored or co-authored 140 original research articles and numerous invited articles and book chapters.  He is a reviewer for several scientific journals.

William C. Gruber

Nanette Cocero is the Global President of Pfizer Vaccines. In her role, Nanette oversees an international business and is responsible for the development and delivery of innovative vaccines that address serious and life-threatening conditions, helping to protect communities around the world.

Nanette leads a global team of 1,500 colleagues and manages a diverse vaccines portfolio aimed at protecting lives at all stages, from infants to older adults. She and her team also partner with governments, civic organizations, and others in the biopharmaceutical industry to accelerate global public health progress. She is Chair of the International Federation of Pharmaceuticals and Manufacturers Association (IFPMA) Vaccine CEO Steering Committee, advocating for policies and practices that will enable greater access and affordability to vaccines in low and middle-income countries. 

Prior to her current position, Nanette was Regional President, Emerging Markets, for Pfizer’s Innovative Health business. In this role, she led business operations in over 100 countries across Latin America, Africa, the Middle East, and Asia, spanning Pfizer’s core therapeutic areas including vaccines, oncology, inflammation and immunology, internal medicine and rare disease. During her 15+ year tenure at Pfizer, Nanette has held numerous leadership positions in both developed and emerging markets, driving continuous growth for the businesses she managed and bringing novel medicines and access solutions to patients.

Before joining Pfizer, Nanette worked for 10 years as a management consultant and served as a Research Fellow for the University of Pennsylvania, Department of Pharmacology. Nanette earned a Bachelor of Science degree in chemistry from Cornell University; a Ph.D. in pharmacology from the University of Pennsylvania, and an MBA from The Wharton Business School. She has lived and worked in the continental United States, Puerto Rico, and Spain and she is bilingual in English and Spanish.



Nanette Cocero

Michael Binks is currently the Vice President of Clinical Research at [Pfizer](/org/pfizer). Michael has previously worked as an Honorary Clinical Fellow at Addenbrookes Hospital in Cambridge, as Head of Translational Medicine for GlaxoSmithKline, and as a Visiting Rheumatologist and Senior Registrar at the [University College London](/org/ucl). 

Binks has been working in the field of clinical research for over 20 years. Michael has experience in a wide range of research areas, including epigenetics, JAK inhibitors, and inflammatory challenge models. Michael has also been involved in the development of new drugs for the treatment of arthritis and other inflammatory conditions. 

Binks is a highly respected researcher who has made significant contributions to the field of clinical research. Michael has played a key role in the development of new treatments for inflammatory conditions, and their work has helped to improve the lives of countless patients.

Michael Binks attended Robert Gordon's College in Aberdeen before studying medicine at [University College London](/org/ucl) (UCL). Michael then undertook their postgraduate training in internal medicine at the Royal College of Physicians in London, before completing a specialist register in rheumatology with the General Medical Council. Michael also has a BSc in immunopharmacology from UCL.

They are on a team with Ken Rhodes - VP, Rare Neurology & Discovery Biology, Greg Larosa - VP, Head of Scientific Research, and Katherine Beaverson - Senior Director, Patient Advocacy Lead - Rare Disease Unit. Michael Binks reports to Seng H Cheng, SVP, Chief Scientific Officer - Rare Disease Unit.

Michael Binks

Rady Johnson is Executive Vice President and [Pfizer](/org/pfizer)’s Chief Compliance, Quality and Risk Officer. He has overall responsibility for the company's global compliance program, Regulatory Quality Assurance organization, global security efforts, and Office of the Ombuds.

Since joining [Pfizer](/org/pfizer) in 1994, Rady has led the Regulatory Law practice group as well as the Corporate Regulatory and Healthcare Law Audit functions, established the Legal Division’s Global Products Counsel practice group, and served as Senior Vice President and Associate General Counsel for the innovative segments of [Pfizer](/org/pfizer)’s Worldwide Biopharmaceuticals Business. Prior to joining the company, Rady was in private practice in Washington, DC, with the law firm of Hogan & Hartson, where he was a member of their food and drug law practice. Previously, Rady was a Certified Public Accountant specializing in the healthcare and hospitality industries for Arthur Anderson. He is a graduate of the [University of Richmond](/org/university-of-richmond) and the Georgetown University Law Center.

Rady was recognized by the Ethisphere Institute in 2015 as an Attorney Who Matters for his work in helping to “pioneer a corporate and industry-wide legacy of ethics and integrity.” He chairs the International Federation of Pharmaceutical Manufacturers & Associations' Ethics & Business Integrity Committee, serves on the board of directors of the Pro Bono Partnership and the Citizens Crime Commission of New York City, is an adjunct professor at the University of Connecticut School of Law, and is very active in many local charities and organizations in his hometown of Westport, CT.

Rady Johnson

Mikael Dolsten focuses on advancing [Pfizer](/org/pfizer)’s scientific breakthrough leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines. He is a member of the Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at [Pfizer](/org/pfizer), which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed medicines and vaccines. WRDM comprises all [Pfizer](/org/pfizer) research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation. The Vaccines R&D team leads scientific efforts from discovery through registration of novel vaccines. Mikael also has worldwide responsibility for [Pfizer](/org/pfizer)’s medical, safety and external R&D innovation, as well as science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining [Pfizer](/org/pfizer) in 2009, Mikael was President of Wyeth Research, where he led scientists involved in all R&D/Medical activities across the US, Europe and Asia. Before that, Mikael served as Executive Vice President and Head of Worldwide Research for [Boehringer Ingelheim](/org/boehringer-ingelheim) from 2003-2008.

Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was Adjunct Professor in Tumor Immunology and was recently appointed Visiting Professor to advice on science and technology strategies. He serves on the PhRMA Research & Development Leadership Forum as well as on the PhRMA Foundation Board of Directors. He is a member of the board of Karyopharm Therapeutics and of Research! America. Additionally, Mikael is a member of the Board of Overseers for the [Scripps Research](/org/scripps-research-institute) Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. Since 2014, Mikael has co-chaired the Accelerating Medicine Partnership with National Institutes of Health (NIH) Director Francis S. Collins. Mikael advised the Obama Administration on regulatory and drug development issues as well as then Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research. Through 2019, Mikael was a council member of the Government-University-Industry Research Roundtable.

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with contributions in molecular cell biology, immunology and oncology.

Mikael Dolsten

Dr. Luis Jodar is Senior Vice President and Chief Medical and Scientific Affairs Officer for Vaccines Medicines Development, Scientific and Clinical Affairs at Pfizer Inc. In this capacity, Dr. Jodar heads and manages vaccines medical, scientific and clinical affairs group worldwide at the global, regional and at the country levels with around 200 MD/PhDs vaccine medical colleagues. Dr. Jodar is also responsible for approving and monitoring clinical vaccine programs post Proof of Concept.

Luis Jodar

Sue Diviney is currently the VP, Office of the Ombuds Lead at [Pfizer](/org/pfizer). Prior to this position, they served as the Senior Director of Employee Relations and a Group Lead at [Pfizer](/org/pfizer) Inc. from 2006 to 2009. From 1997 to 2009, Diviney was also an Associate at Epstein Becker & Green, P.C.

Sue Diviney attended Walt Whitman High School before going to [Stony Brook University](/org/stony-brook-university) for their Bachelor's Degree in Social Welfare. Sue then attended St. John's University School of Law to earn their Juris Doctor (J.D.) degree.

They work with Carol Bye - VP, Regulatory Quality Assurance, Lev Kubiak - VP, Chief Security Officer, and Guy Delp - VP, Global Information Security. Sue Diviney reports to Rady Johnson, EVP, Chief Compliance, Quality & Risk Officer.

Sue Diviney

Eric Aaronson is the SVP, Chief Counsel - Corporate Affairs, IP & IP Enforcement at [Pfizer](/org/pfizer). Eric was previously with [Kaye Scholer LLP](/org/kaye-scholer-llp) from September 1995 to October 2000 as litigation.

Eric Aaronson has a JD from New York University School of Law and a BA with Honors from [Binghamton University](/org/binghamton-university).

They are on a team with Sheila Brodbeck - SVP, Chief Litigation Counsel, Bryan Supran - SVP, Deputy General Counsel. Eric Aaronson reports to Doug Lankler, EVP, General Counsel.

Eric Aaronson

Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer at [Pfizer](/org/pfizer), responsible for developing and implementing an enterprise-wide digital strategy. Lidia leads all digital, data and technology solutions across the company.

She spearheads several transformational programs and initiatives to support [Pfizer](/org/pfizer)’s purpose of delivering Breakthroughs that Change Patients’ Lives applying digital capabilities and products including: digitizing drug discovery and development; improving health outcomes and patient experiences; improving operational processes through automation and robotics; and delivering powerful insights with advanced data and analytics for better decision-making.

Lidia leads the effort to create [Pfizer](/org/pfizer)’s Advanced Analytics Platform that brings together data from [Pfizer](/org/pfizer) and external partners as well as tools to model scientific and clinical decisions, patterns and insights. She is also driving initiatives to re-imagine clinical trials through robotics/automation and tech-enabled processes that enhance patient, provider and site experiences, improve selection and recruitment, and reduce clinical trial cycle times.

Lidia led the effort to launch [Pfizer](/org/pfizer)’s Digital Companion™, a suite of digital products and solutions for every therapy to deepen engagement between patients and physicians for better outcomes. She recently collaborated to deliver five [Pfizer](/org/pfizer) Digital Companions™: Mabu Wellness Coach for patients, Champix Chatbot to assist with smoking cessation, LivingWith app to support patients, and their loved ones, undergoing cancer treatment, drone medicine delivery in the Dominican Republic to increase patient access to medicines in remote and difficult-to-reach locations, and a partnership with [Fitbit](/org/fitbit) to drive timely diagnosis of atrial fibrillation.

She also leads initiatives to empower [Pfizer](/org/pfizer) colleagues, simplifying and automating their work with robotics, machine learning, and predictive analytics that enable better and faster decisions, while driving efficiencies. In 2019, [Pfizer](/org/pfizer) automated 30 percent of approximately 100 million transactions across the company.

In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. Lidia led the effort to create Quest's innovative Quanum Solutions brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs.

Lidia was named a Healthcare Transformer by Medical, Marketing & Media in 2019. In 2018, she was the only diagnostics provider executive to participate in the White House Artificial Intelligence Summit. She received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts. Lidia was a founding member of Synaptic Health Alliance, that includes leading healthcare companies Aetna, Ascension Health, Humana, MultiPlan, Optum, Quest Diagnostics and United Health Group, using blockchain technology to improve provider data quality, which will serve as a new distributed partnership model that can be used to tackle other industry-wide data issues.

Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA). She also was a board member of Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA from 2016 to 2018. She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business. Lidia is married and has two children.

Lidia Fonseca

Dr. Gottlieb, a physician and medical policy expert, is currently a Special Partner of New Enterprise Associations, Inc.’s healthcare investment team and a Resident Fellow of the [American Enterprise Institute](/org/american-enterprise-institute). He served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors, including serving as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and as a Senior Adviser to the Administrator of the [Centers for Medicare and Medicaid Services](/org/centers-for-medicare-and-medicaid-services), where he helped implement the Medicare drug benefit, advance policies to improve healthcare quality and promote the effective use of new medical technologies.

Scott Gottlieb

Current Senior Advisor and Board member of the [Bill & Melinda Gates Medical Research Institute](/org/bill-melinda-gates-medical-research-institute). Former Chief Executive Officer of the [Bill & Melinda Gates Foundation](/org/bill-melinda-gates-foundation) from 2014 until 2020. Prior to joining the [Bill & Melinda Gates Foundation](/org/bill-melinda-gates-foundation), she was the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF), from 2009 until 2014, where she still serves as an adjunct professor. From 1995 through 2009, Dr. Desmond-Hellmann was employed at [Genentech](/org/genentech) where she served as President of Product Development from 2005 to 2009 overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining [Genentech](/org/genentech), Dr. Desmond-Hellmann was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. Director of Facebook Inc. from 2013 to 2019 and [Procter & Gamble](/org/procter-gamble) from 2010 to 2017. Pfizer Director since 2020. Member of our Governance & Sustainability Committee and Science and Technology Committee.

Susan Desmond-Hellmann

Mr. Quincey is Chairman and Chief Executive Officer (CEO) of [The [Coca-Cola](/org/coca-cola) Company](/org/the-coca-cola-company). He has held the position of Chairman of the Board of [The [Coca-Cola](/org/coca-cola) Company](/org/the-coca-cola-company) since 2019 and CEO since 2017. Prior to becoming CEO, he served as President and Chief Operating Officer from August 2015 to 2017. Since Mr. Quincey joined [The [Coca-Cola](/org/coca-cola) Company](/org/the-coca-cola-company) in 1996, he has held a number of leadership roles around the world, including President of the Europe Group, President of the Mexico division and President of the South Latin division. Prior to joining [Coca-Cola](/org/coca-cola), he was a partner in strategy consulting at The Kalchas Group, a spinoff of [Bain & Company](/org/bain) and McKinsey.

Mr. Quincey serves as vice co-chair of The Consumer Goods Forum and is a founding member of the New York Stock Exchange Board Advisory Council.

Pfizer

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Behind the scenes

Values

Joy

Equity

Excellence

Courage

Discover similar companies